IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide and is the most common cause of chronic kidney disease (CKD) in China. It lacks recommended treatment in refractory IgAN after conventional therapy. Belimumab, a recombinant human IgG-1λ monoclonal antibody that inhibits the B lymphocyte stimulator, is recommended to treat active lupus nephritis. This report presents a case of a child with severe and refractory IgAN who showed kidney response after belimumab addition combined with conventional therapy. The therapy result was accompanied by decreased plasma cells in peripheral blood. It is the first case showing the benefits of adding belimumab to other immunosuppressive regimens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00467-024-06620-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The beneficial effect of adding belimumab in severe and refractory IgA nephropathy: a case report.
Pediatr Nephrol
January 2025
Department of Nephrology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide and is the most common cause of chronic kidney disease (CKD) in China. It lacks recommended treatment in refractory IgAN after conventional therapy. Belimumab, a recombinant human IgG-1λ monoclonal antibody that inhibits the B lymphocyte stimulator, is recommended to treat active lupus nephritis.
View Article and Find Full Text PDFAn overlapping case of IgG4-related disease and systemic lupus erythematosus treated with belimumab: a case-based review.
Rheumatol Int
March 2024
Department of Rheumatology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
IgG4-related disease (IgG4-RD) is a systemic condition in which IgG4 plasma cell infiltration and fibrosis cause organ swelling and lead to diverse clinical manifestations. Although IgG4-RD typically responds to glucocorticoids (GCs), relapse during tapering occurs and an early GC-sparing approach might therefore be beneficial. Systemic lupus erythematosus (SLE) is a chronic inflammatory disease with multiple symptoms that is also treated with GCs as a first-line therapy.
View Article and Find Full Text PDFRepeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center.
Lupus
October 2023
Nephrology Unit, Fernández Hospital, Buenos Aires, Argentina.
Background: Lupus nephritis affects 40 to 70% of Systemic Lupus Erythematous(SLE) patients increasing their morbi-mortality; therefore, successful treatments are required to improve outcomes.
Research Design And Study Sample: In this paper 20 patients who participated in the BLISS LN trial at a single center (OMI) in Argentina were studied. All the patients continued Mycophenolate (MMF) treatment when the trial was finished and until a second biopsy was performed to determine the withdrawal of the immunosuppression according to the achieved clinical and histological response.
Experience with abatacept in refractory lupus nephritis.
Rheumatol Int
December 2023
Hospital Universitario Doctor Peset, Valencia, Spain.
Lupus nephritis is a major cause of morbidity in patients with systemic lupus erythematosus. Responsiveness to treatment is crucial to avoid chronic kidney disease. New molecules have been developed in recent years to improve renal survival rates.
View Article and Find Full Text PDFWhen should targeted therapies be used in the treatment of lupus nephritis: Early in the disease course or in refractory patients?
Autoimmun Rev
January 2024
Division of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilians-University, Munich, Germany.
Article Synopsis
- Lupus nephritis (LN) is a serious kidney problem that can still cause kidney failure in some patients, even with better treatments today.
- New drugs like belimumab and voclosporin can help improve kidney health when used alongside standard treatments.
- Doctors are debating whether to use these new drugs early on for all patients or only for those who are having trouble with their current treatment, considering costs and risks involved.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!